Lipoproteins and Cardiovascular Disease: Biological Basis and Epidemiological Studies

Value in Health

Volumn 1, Issue 2, 1998, Pages 105-109

  Castelli, William ^a  

^a Framingham Cardiovascular Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000408981     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.1998.120105.x     Document Type: Conference Paper

References (31)

1. The GUSTO Angiographic Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673.
2. Plotnick CD, Corretti MC, Vogel GA. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA 1997;278:1682-6.
3. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915.
4. Wilson PR, Myers RH, Larson MC, et al. Apoprotein E alleles, dyslipidemia and coronary heart disease. The Framingham Offspring Study. JAMA 1994;272:1666.
5. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res 1992;33(4):447-54.
6. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328(20):1444-9.
7. Stephens NG, Parsons A, Schofield PM, et al. Randomized controlled trial of Vitamin E in patients with coronary disease: Cambridge Heart Anti-Oxidant Study (CHAOS). Lancet 1996;347(9004):781-6.
8. Pietinen P, Ascherio A, Korhonen P, et al. Intake of fatty acids and risk of coronary heart disease in a cohort of Finnish men. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Epidemiol 1997;145(10):876-87.
9. Morris DL, Kritchevsky SB, Davis CE. The Lipid Research Clinics Coronary Primary Prevention Trial and Follow-up Study. JAMA 1994;272(18):1439-41.
10. Bostom AG, Cupples LA, Jenner JE, et al. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 1996;276(7):544-8.
11. Garber AM, Browner WS, Hulley SB. Clinical guidelines, part 2: cholesterol screening in asymptomatic adults, revisited. Ann Intern Med 1996;124(5):518-31.
12. Manolio TA, Pearson TA, Wenger NK, et al. Cholesterol and heart disease in older persons and women: review of an NHLBI workshop. Ann Epidemiol 1992;2:161.
13. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study. Can J Cardiol 1988;4:5A.
14. Adult Treatment Panel II. Summary of the second report of the National Cholesterol Education Pro grain (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 1993;269:3015-23.
15. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995;76:69C-77C.
16. Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation 1983;67:4.
17. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
18. Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease. N Engl J Med 1980;302:1383-9.
19. Austin MA. Plasma triglycerides as a risk-factor for coronary heart disease. The epidemiological evidence and beyond. Am J Epidemiol 1989;129:249-59.
20. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1997;3:213-9.
21. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595.
22. Kaplan NM. The deadly quartet and the insulin resistance syndrome: an historical overview. Hypertens Res 1996;19(Suppl 1):S9-S11.
23. Carmelli D, Selby JV, Quiroga J, et al. 16-year incidence of ischemic heart disease in the NHLBI twin study. A classification of subjects into high- and low-risk groups. Ann Epidemiol 1994;4(3):198-204.
24. Austin MA, King M-C, Vranizan KM, Krauss RM. Atherogenic lipoprotein particle size and number to plasma triglyceride concentration. Arteriosclerosis 1985;5:381.
25. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996;124(Suppl):1-9.
26. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
27. Downs JR, Clearfield M, Weiss S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Presented at the American Heart Association, Orlando, Fla, Nov 1997. JAMA 1998;279(20);1615-22.
28. Farmer JA, Gotto AM Jr. Dyslipidemia and other risk factors for coronary artery disease. In: Braunwald E, Heart Disease, 5th ed., Philadelphia: Saunders, 1997.
29. Williams RR, Hunt SC, Hasstedt SJ, et al. Are there interactions and relations between genetic and environmental factors predisposing to high blood pressure? Hypertension 1991;8(Suppl 3): 129-37.
30. Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 1995;44(4):369-74.
31. Sirtori CR. The physiopathology and pharmacological approach to multiple metabolic and blood coagulation syndromes, the characteristics of atherogenesis [Italian]. Cardiologia 1991;36(12 Suppl 1):7-14.